You can ask for it.

Tucatinib is a new HER2-TKI in the pipeline. What’s different about this one? It shows early promising activity in combo with capecitabine for HER2-positive breast cancer metastatic to the brain and/or refractory to other HER2 agents. | Murthy, Lancet Oncol 2018